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Abstract 
Health Technology Assessment (HTA) methods have become a standard part of decision-making processes in 
healthcare service. Although it is routinely applied in drugs and surgery, HTA in medical devices is still quite 
challenging. The reason is that the main objective of HTA studies for devices is not optimization of the cost-
effectiveness ratio, but rather decisions about procurement and/or incorporation of the device. The clinical benefit is 
not expressed in terms of quality of life, but in the rate of diagnostic yield, and in the extent to which the technology 
makes the therapy shorter and/or more patient-friendly. Utilization of multiple-criteria decision-making methods for 
evaluation of the aggregated clinical, technical and user´s effect (outcome) is recommended as the input to cost-
effectiveness analyses. Different methods are derived for strategic and/or operational assessment of new technology. 
Other studied problems are identification of requirements for medical device selection and purchase, composition of 
expert panels, and assessment of medical device maintenance demandingness. 
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Introduction 
 
Limited resources and continuously growing costs in 
health care have led to the necessity to assess 
effectiveness, appropriateness and costs of health 
technologies, i.e. drugs, biologics, devices, equipment 
and supplies, medical and surgical procedures, support 
systems, and organizational and managerial systems in 
health care [20, 22].  
Health Technology Assessment (HTA) comparing 
clinical outcomes and costs of interventions has 
established as a standard method in drug 
reimbursement process worldwide since the 1990s 
[22, 56]. However, its potential is much wider. From 
the beginning, it was stressed that this method can be 
used to assess all kinds of health technologies, which 
has been attempted with varying success. HTA 
utilization to medical devices has been a challenge 
until today [14, 39, 46].  
This paper summarizes the results reached in this 
field by the CzechHTA group within last five years, 
when they concentrated on HTA methods applied to 
devices under a grant of the Ministry of Health of the 
Czech Republic. 
 
Principal methods of HTA 
 
The core methods of HTA are different cost analyses 
[8, 22, 56]. The frequently used ones are listed in 
Table 1.  
Tab. 1: The most frequent cost analyses of HTA 
 
Analysis 
type Outcomes Costs ZĞŵĂƌŬ 
Cost-
benefit 
analysis 
(CBA) 
Transformed to 
(measured in) 
money units 
(CZK, EUR, 
USD, etc.) 
Expressed 
as one 
figure 
(total) in 
money 
units 
Expressing the 
outcomes (the 
price of a 
human life) in 
money units is 
quite 
challenging 
Cost-
effectiven
ess 
analysis 
(CEA) 
Expressed as 
one figure in 
natural units 
(e.g. number of 
life-years 
saved, 
incidence of the 
disease etc.) 
Expressed 
as one 
figure 
(total) in 
money 
units 
The most 
common 
analysis used 
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Cost-
utility 
analysis 
(CUA) 
Expressed in 
QALYs (i.e. 
quality-adjusted 
life-years) 
Expressed 
as one 
figure 
(total) in 
money 
units 
A special type 
of CEA 
Cost-
conseque
nce 
analysis 
(CCA) 
Listed in 
natural units 
Listed in 
money 
units 
Outcomes and 
costs are report-
ed separately, 
no ratio is 
calculated 
 
The most widely used method is the cost-
effectiveness analysis (CEA). It compares costs, C, 
expressed in monetary units, with outcomes (also 
called effects), E, expressed in natural units in the cost-
effectiveness ratio, C/E: 
 
(1) 
 
If two interventions are to be compared (e.g. a new 
drug with the standard drug, a surgery with a 
conservative intervention, or two different imaging 
modalities), the incremental cost-effectiveness ratio, 
ICER, is often calculated instead of two full C/E ratios: 
 
(2) 
 
Thus, ICER is the ratio of the change in costs to 
incremental benefits of the intervention. The cost-
utility analysis (CUA) and the cost-benefit analysis 
(CBA) are special kinds of CEA. In CUA, the outcome 
(called the utility in this case) is expressed in QALYs, 
quality-adjusted life years, which is a parameter 
combining the length of life gained (in years) with its 
quality. One QALY is equal to a one-year life in full 
quality, or to a 2-year life in 50% quality, or for 
example, to a 15-month life in 80% quality. The utility 
is measured by patient self-reporting; the best-known 
surveys are EQ-5D by EuroQoL and SF-36 by the 
Medical Outcomes Trust. CUA is considered a 
standard for assessments of new pharmaceuticals. In 
other technologies, however, other analyses may be 
more frequent.  
The cost-benefit analysis (CBA) is based on 
expressing the outcome in money units. Its roots are in 
the welfare economics, and it is frequently used by 
governments to appraise their policies and/or 
investments (for typical applications, see e.g. [19, 24, 
57, 64]). In HTA, however, it has been used much less 
frequently, as it requires expressing the intervention 
outcomes in monetary units. This, in fact, means 
finding an equivalent for the quality of life (and 
consequently for the human life) in a monetary form. 
Many criticize this approach from the ethical point of 
view [9, 25, 63]. 
The challenges of cost analyses are sometimes 
avoided by using the cost-consequence analysis (CCA). 
This approach resigns from the ambition of calculating 
one ratio; instead, separate lists of (various) outcomes 
and costs are compiled. Hence, it is a more descriptive 
method. 
 
 
Specificities of medical devices  
 
Medical devices can be divided according to their 
purpose to therapeutic and diagnostic. While the 
former group allows assessment of clinical outcomes 
similarly to drugs, the situation is much more complex 
in the latter group. These are usually relatively 
expensive technologies requiring the perspective of a 
hospital or a region as a whole. Thus, the main goal of 
HTA studies is not to optimize the cost-effectiveness 
ratio, but to support decisions about procurement 
and/or incorporation of the device. The clinical benefit 
is not expressed in terms of quality of life, but rather in 
the rate of diagnostic yield. Another important issue is 
also the moral lifetime of the device; rapid upgrades 
pressurize researchers into assessing devices 
immediately, without much experience, and in a shorter 
time, which does not allow for sufficient clinical 
experience [14, 39, 46]. 
Recently, Santos, Tavares et al. published a series of 
papers describing the specificities of medical devices 
from the point of view of the product development 
process [53, 54]. They point out above all that medical 
devices create a regulated industry, similarly to the 
automotive or nuclear industries; this is a very dynamic 
branch with permanent changes and a short lifetime of 
products. Manufacturers have many obligations even 
after selling the device, namely post-market surveil-
lance and adverse event reporting. In case of adverse 
events, they should take action. Moreover, the field is 
very sensitive to ethical and economic issues. Similar 
problems appear if we decide to submit medical 
devices to HTA methods. 
In 2009, Value in Health published two papers 
summarizing arguments for equal or different character 
of drugs and medical devices in economic evaluations 
[14, 62]. While Taylor and Iglesias [62] stood up for an 
equal approach, Drummond et al. [14] listed the main 
problems that a researcher encounters when assessing 
medical devices. The following list is a slight 
modification of their reasons, why assessments of 
medical devices differ from assessments of 
pharmaceuticals:  
- many medical devices are diagnostic, hence the 
outcome cannot be separated from the treatment 
and, moreover, most such devices have multiple 
applications; 
- due to short life cycles in medical devices, their 
frequent modifications, and the existence of 
“learning curves”, there is unlikely to be a 
substantial steady-state period, during which the 
device could be evaluated in a randomized 
controlled trial;  
ORIGINAL RESEARCH 
 
 
25 
 
- in addition, it is generally impossible to undertake 
blinded studies with medical devices; 
- the efficacy of a device depends not only on the 
device itself, but also how it is used (e.g. the skill 
and experience of the surgeon); 
- implementation of a new therapy involving a device 
can have wider economic implications; 
- equivalent clinical evidence may not be available 
for all products, making comparisons difficult; 
- prices are likely to change over time, because new 
better products enter the market, or because of the 
ways, in which procurement takes place in many 
health care systems. 
Especially the problems with carrying out larger 
randomized controlled trials can be hardly overcome, 
and the problems with determining QALYs due to 
impossibility of patient self-evaluation disqualify the 
CUA. The situation calls for a special methodology for 
HTA studies in medical devices, quite different from 
that for drugs [46]. 
Example 1. CEA/CUA for an electronic (C-Leg) 
versus mechanic prostheses [36]. A socio-economic 
comparison of the electronic prosthetic joint C-Leg and 
a mechanical prosthetic joint in patients with a 
transfemoral amputation can serve as an example of a 
typical HTA study. As the artificial knee can be 
classified as a therapeutic device, the cost analysis 
causes no significant difficulties. The study involved 
42 patients with a high grade of activity in six 
prosthetic centres in the Czech Republic. The time 
horizon was four years (the lifetime of special femoral 
prostheses) and the effect was assessed using the PEQ 
questionnaire that has nine dimensions [6]. The 
dimension of walk was used as the effect in the CEA. 
Next to that, QALY was assessed using the EQ-5D 
questionnaire [16], and used in the CUA. Costs were 
calculated from the perspective of a health insurance 
company. The results of the cost-effectiveness analysis 
and the cost-utility analysis are shown in Table 2. 
Tab. 2: CEA/CUA results comparing C-Leg and a 
mechanical knee prosthesis [36] 
 
 C-Leg Mechanical 
PEQ – number of dimensions 
dominated 9 0 
PEQ dimension “walk”  
(used as an effect in CEA) … E 82.22 65.87 
Direct costs (prosthesis production 
and 4-year servicing) ... C [CZK] 608 872 552 351 
Cost-effectiveness ratio ... C/E 7405.4 8385.5 
ICER 3456.9 
EQ-5D … [QALY] 3.52 3.20 
Cost-utility analysis [CZK/QALY] 172 975 172 610 
ICER 176 628 
The cost-effectiveness analysis speaks in favour of 
C-Leg, while the cost-utility analysis slightly 
prioritizes the mechanical prosthesis. However, the 
ICER value calculated from the cost-utility data is 
176 628 CZK/QALY, which is far below the 
recommended threshold of three times GDP per capita 
for each DALY1 averted (i.e. QALY gained) [68]. 
From this point of view, C-Leg is a cost-effective 
option. 
 
 
Multiple-criteria decision analysis 
as the main method in medical 
device assessment 
 
The principal difficulty in any evaluation of 
technology consists in solving the problem of 
evaluating the effective component of instrumentation. 
Instrumentation may not directly affect the parameters 
associated with the quality of life, nevertheless, it 
affects the quality of therapeutic and diagnostic 
processes, the attending physician’s way of working 
and, last but not least, the patient’s comfort [36]. When 
evaluating the quality of medical devices, data such as 
technical specification of individual devices, 
information about their control, failure rate, quality of 
results, etc. are largely analysed. No standard 
procedure has been decided for such evaluations yet.  
In this paper, evaluating the effect of medical devices 
using multiple-criteria decision analysis (MCDA) [23, 
60] is suggested. The multiple-criteria decision-making 
(MCDM) techniques have been used in both evaluation 
and selection of equipment [30, 35]. Balestra et al. [1] 
applied the analytic hierarchy process (AHP) to support 
the acquisition of pacemakers and implantable 
defibrillators. Chatburn and Primiano [10] used the 
AHP to select and purchase ventilators for an intensive 
care unit. Pecchia et al. [43] designed a CT scanner 
selection approach based on 12 specifications. 
Montevechi et al. [40] used AHP for ultrasonic 
scanning system selection in private hospitals in Brazil. 
Sloane et al. [59] demonstrated how to build a neonatal 
ventilator evaluation model. In addition, Santos and 
Garcia [52] used AHP, multi-attribute failure mode 
analysis (MAFMA) and elimination and choice 
expressing reality (ELECTRE) to demonstrate a 
decision model for incorporating indicators into the 
acquisition of hospital medical equipment. 
These and other studies indicate the possibility to use 
MCDA in HTA. A frequently discussed option is a 
total replacement of CEA with MCDA [2, 66]. 
However, this approach challenges serious 
consideration of cost [11]. Instead, we recommend 
                                                 
1 DALY, disability-adjusted life years, can be practically understood 
as inverse values to QALY; however, these terms originate from 
different disciplines, and hence they can give slightly different values 
[55].  
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maintaining CEA as the main tool, and utilizing 
MCDA only for evaluation of the effects (outcomes) 
[45]. Thus, the value used for decisions will be the 
ratio of outcomes evaluated by means of MCDA, and 
costs in their natural expression. Next to MCDA, 
value-engineering methods can also be used. This 
approach allows us to assess medical devices based on 
their technical data, which is impossible in the standard 
pharmacoeconomic methodology. 
Two different procedures are recommended. A full 
AHP process combined with the Delphi method is time 
and capacity consuming [30], and can be used above 
all for strategic decision-making [35]; this will be 
described in the next section. A simplified procedure 
suitable for operative management at the hospital/clinic 
level utilizes simpler MCDA methods [32, 45]; this 
approach will be the topic of the next but one section. 
 
 
Medical device evaluation for 
strategic purposes 
 
In order to be able to evaluate medical devices, the 
problem must be described in a satisfactory detail. The 
knowledge of the values of all selected criteria 
(specifications) is essential for all individual device 
models to be covered by the evaluation. The 
availability of the assessed models in the respective 
market is usually also assumed. A satisfactorily 
detailed description must also be provided if the 
analysis is calculated in any field different from 
medical devices.  
To determine the weights of the main specifications 
of the medical device assessed, we propose, within the 
framework of MCDA, to use a web-oriented means of 
polling, using Saaty´s analytic hierarchy process (AHP) 
[49,50,51] and the Delphi multi-round polling 
procedure [12]. In the first round, the experts compare 
the key parameters for the selection of the medical 
device and then compare the available choices relative 
to each parameter. Data received from the experts are 
processed to determine the mean and extreme values of 
the evaluations. The first-round results are reported to 
the experts. If an expert’s evaluation deviates 
significantly from the weighted mean value, the expert 
is asked to either provide reasons for the opinion or to 
correct it. Consecutive rounds follow the same scheme. 
According to [42], after three to four rounds, the 
responses become stable and do not require any more 
changes usually. During the survey, the experts’ 
responses remain anonymous, in order to avoid the 
influence of authorities. 
MCDA methods are designed for a mutual 
comparison of several (n > 2) variants (e.g. devices). 
Each variant is described by a set of parameters – 
hence, we obtain a matrix, the rows of which are 
formed by individual variants, and the columns by 
values of parameters. Several requirements are 
established for the parameter values, namely the 
optimising criteria. These criteria can be maximising 
(the higher the value, the better), or minimising (the 
lower the value, the better). Our task is to order the 
variants based on these criteria from the best to the 
worst (it is often sufficient to find the best variant) 
[23]. 
The Delphi method does not lead to a full agreement 
in experts’ opinions. Here, we take into account the 
opinion of each expert individually. We compare 
individual pairs of criteria in a square matrix, where we 
determine the preference measure of the row criterion 
over the column criterion. Then we complete the 
matrix symmetrically according to the main diagonal 
with inverse values, and place the value one to the 
main diagonal (no criterion can dominate itself); what 
we create is the so-called Saaty´s matrix (see Table 3) 
[49]. The resulting weights of criteria are obtained as 
geometric averages of the lines that are subsequently 
normalized.  
 
Tab. 3: Saaty´s matrix – an example. 
 
 
Criterion C1 C2 C3 C4 
C1 1 3 2 6 
C2 1/3 1 1/2 1 
C3 1/2 2 1 3 
C4 1/6 1 1/3 1 
 
After selecting and evaluating the criteria, the group 
of experts evaluates each alternative (i.e. each device 
included in the assessment process) according to each 
selected criterion. The result consists of n Saaty´s 
matrices, where n is the number of criteria. It is 
necessary to check the consistency of each obtained 
Saaty´s matrix. We assess this using the consistency 
index CI: 
 
(3) 
where  is the largest eigenvalue of the Saaty´s 
matrix and n is the number of alternatives. The matrix 
is considered consistent if CI/RI < 0.1, where RI is the 
consistency index in the case of randomly generated 
results. Otherwise, the expert responsible for the 
inconsistent value is asked to correct his/her 
evaluations [29]. 
Eventually, the results for individual criteria are 
combined using the previously determined weights of 
the criteria. We can also determine the weights of 
individual experts in the expert group. In this case, the 
weights of experts are also used in this step. 
Example 2. Selection of a mammography device 
[36]. Let us illustrate this procedure using a model 
selection of mammography equipment. The list of 
parameters important for the choice was determined 
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taking into account expert opinions, requirements of 
medical facilities in the past and the literature review 
(especially [15]). The following parameters were 
chosen: (i) the X-ray focal spot size, (ii) the detector 
size, (iii) the modulation transfer function (MTF), and 
(iv) the detective quantum efficiency (DQE). Other 
parameters considered important (space necessary for 
device installation, device mass) were omitted, as they 
are important only in the case of technical limitations. 
If necessary, the evaluation of technical parameters can 
be extended adding further parameters. 
The assessment was done for five devices that are 
currently available in the Czech market and that are 
destined for screening centres. Their producers and 
exact commercial names are not important for 
methodology illustration. Their parameters are given in 
Table 4. 
 
Tab.4: Technical parameters of the assessed devices. 
 
Alterna-
tive 
DQ
E@
 
5 
lp
/m
m
 
M
TF
@
 
5 
lp
/m
m
 
DQ
E@
 
1 
lp
/m
m
 
Fo
ca
l s
po
t 
si
ze
 [m
m
] 
De
te
ct
or
 
si
ze
 [c
m
] 
Device #1 25% 50% 60% 0.1 and 0.3 19u23 
Device #2 35% 68% 50% 0.1 and 0.3 24u29 
Device #3 25% 55% 50% 0.1 and 0.3 24u30 
Device #4 30% 60% 60% 0.1 and 0.3 24u30 
Device #5 45% 65% 65% 0.1 and 0.3 24u30 
 
 
The next step is the proper evaluation of the selected 
parameters importance. Individual qualitative and 
quantitative characteristics are represented by colour 
bands; the evaluators (five experts were consulted; 
their choices will be discussed below) can move them 
using the cursor, which expresses their preferences 
between each compared pair of parameters. 
Subsequently, the evaluators compare the assessed 
devices for each parameter in the same way. The 
results are presented in the form of Saaty´s matrices 
(see Table 5 and Table 6). 
Tab. 5: Saaty´s matrix for parameter weights determi-
nation. 
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DQE@ 
5 lp/mm 
1 0.75 1.56 0.15 0.22 0.52 0.092 
MTF@ 
5 lp/mm 
1.33 1 1.78 1.70 1.38 1.41 0.248 
DQE@ 
1 lp/mm 
0.64 0.56 1 0.79 0.30 0.61 0.107 
Focal 
spot size  
6.67 0.59 1.27 1 8.10 2.10 0.368 
Detector 
size 4.55 0.72 3.33 0.12 1 1.06 0.185 
 
 
 
Tab. 6: Saaty´s matrix evaluating individual devices 
according to SQE values. 
 
 
De
vi
ce
 #
5 
De
vi
ce
 #
4 
De
vi
ce
 #
3 
De
vi
ce
 #
1 
De
vi
ce
 #
2 
Device #5 1 1.857 1 2.448 2.704 
Device #4 0.539 1 1 1.564 0.724 
Device #3 1 1 1 1 0.613 
Device #1 0.409 0.639 1.270 1 0.724 
Device #2 0.370 1.381 1.632 1.381 1 
 
The normalized weights of parameters of individual 
devices are included in one matrix (see Table 7), and 
this is multiplied by the vector of normalized parameter 
weights (see Table 5). If we are given the weights of 
expert competences (in this case they are given in 
Table 8), we can use them in the last step of the 
analysis (otherwise, this step is skipped). The final 
order of devices is given in Table 9. 
 
 
Tab. 7: Normalized weights of key parameters for 
individual devices. 
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Device #5 27% 21% 23% 23% 23% 
Device #4 20% 19% 20% 21% 22% 
Device #3 18% 19% 19% 20% 22% 
Device #1 16% 18% 20% 19% 14% 
Device #2 19% 22% 18% 18% 19% 
 
 
 
Tab 8: Expert competency weights. 
 
Expert # 1 2 3 4 5 
Expert 
weight 0.595 0.425 0.765 0.680 0.595 
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Tab 9: Final order of devices. 
 
 Evaluation Order 
Device #5 1 1st 
Device #4 0.88 2nd 
Device #3 0.85 3rd 
Device #2 0.83 4th 
Device #1 0.75 5th 
  
 
 
Medical device evaluation for 
operational purposes 
 
Although the method described in the previous 
section seems to be quite sophisticated, it is also time 
consuming. However, the selection must often be 
carried out in a short time. In this section, we present 
an alternative procedure that represents a compromise 
between the precision and time requirements. The basic 
procedure and the links between individual methods 
used are displayed in Figure 1. Its individual blocks are 
described further below. 
 
 
Fig. 1: Flowchart of medical device operative 
selection. 
 
The procedure consists in a combination of a value 
engineering and a MCDM methods. Different methods 
were tested [32, 45]; the best combination proved to be 
Saaty´s matrix [3, 23] used to determine the 
parameters’ normalized weights, combined with the 
TOPSIS2 method [3, 23] used for evaluation of the 
devices themselves. 
                                                 
2 TOPSIS is an abbreviation of the Technique for Order of Preference 
by Similarity to Ideal Solution, originally suggested by Hwang and 
Yoon [27]. 
The method is intended for hospitals making 
decisions about purchasing a new device. The group 
taking the decision is usually composed of a senior 
consultant (or more clinicians), a biomedical engineer, 
the financial manager, and a charge nurse. 
The Saaty´s matrix method is based on an evaluation 
of relative significances; decisions on how many times 
the i-th indicator is more significant than the j-th one 
are entered in the respective fields of a square matrix 
by integers vi. The other value of the compared pair is 
set as the inverse value 1/vi. Such a matrix is shown in 
Table 10. 
 
Tab. 10: Pair-wise comparison (Saaty´s) matrix. 
 
Index 1 2 … J … K … n 
1 1 s1;2 … s1;j … 
 
… s1;n 
2 
 
1 … 
 
… s2;k … s2;n 
… … … 1 … … … … … 
j 
 
sj;2 … 1 … 
 
… sj;n 
… … … … … 1 … … … 
k sk;1 
 
… sk;j … 1 … sk;n 
… … … … … … … 1 … 
n 
  
… 
 
… 
 
… 1 
 
 
The evaluation itself is performed by means of 
eigenvalues of Saaty´s matrix. Individual steps of the 
calculation are as follows: 
1) The sums of all n elements sik, of each k-th 
column of Saaty´s matrix are calculated, 
 
 
(4) 
2) Individual elements in each column are divided 
by these sums. We obtain elements tij of a new 
matrix T, 
 
 
 
 
(5) 
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3) Now we calculate line sums of the matrix T, i.e. 
the sums of all elements tij in the j-th line, 
 
(6) 
and the sum of all tij in the matrix T: 
 
 
(7) 
4) Quantified values of relative significances of 
indicators vj are subsequently calculated by the 
normalisation of the sums in individual lines, 
 
 
(8) 
The TOPSIS method is based on selecting the 
alternative that is closest to the ideal alternative 
represented by the vector (H1, H2,…, Hk), and farthest 
from the basal alternative represented by the vector 
(D1, D2,…, Dk). First, the normalized criterion matrix 
R=(rij) must be created using the formula 
 
 
 
(9) 
 
where i = 1,2,…,p and  j = 1,2,...,k. After this 
transformation, the columns of the matrix R form unit 
vectors. Subsequently, the weighted criterion matrix W 
is calculated so that each j-th column of the normalized 
criterion matrix R is multiplied by the corresponding 
weight vj, that is 
 
 
(10) 
 
The next step is a determination of the ideal (H) and 
the basal (D) alternatives with respect to the weighted 
criterion matrix W. The formula for calculation of the 
distance from the ideal alternative is 
 
 
(11) 
 
and the formula for calculation of the distance from the 
basal alternative is 
 
(12) 
The distances from the basal and the ideal alternative 
are used for computation of the relative indicator of the 
distance from the ideal alternative ci using the formula 
 
(13) 
 
Now, individual variants are ranked according to ci’s 
from the most suitable variant to the least suitable one. 
Example 3. Lung ventilator assessment [45]. The 
data for lung ventilator assessment were collected from 
two university hospitals in the Czech Republic and 
from companies present on the Czech market, based on 
a detailed market research. Similarly to Example 2, the 
producers and exact commercial names are not 
important for methodology illustration. The source data 
for the lung ventilator assessment are given in Table 
11, and the prices of the devices are shown in Table 17. 
 
Tab. 11: Input parameters for lung ventilator asses-
sment. 
 
  
Device 
#1 
Device 
#2 
Device 
#3 
Device 
#4 
Cost of 
consumables 
[CZK/patient/
24 hours] 
19 590 19 590 13 840 8 400 
Cost of spare 
parts 
[CZK/year] 
9 468 9 468 5 800 7 500 
Cost of service 
[CZK/year] 7 400 7 400 5 300 4 300 
Size of device 
[mm3] 
243 
897 
226 
606 
180 
377 
156 
406 
Connection to 
CIS  0.00 1.00 1.00 1.00 
Weight of 
device [kg] 32.80 42.30 44.20 36.30 
 
In the cost-effectiveness ratio, costs are shown in the 
numerator, while effects are represented in the 
denominator. However, in this example, some criteria 
(effects in the cost-effectiveness language) are also 
prices. These are the parameters that can significantly 
affect the economy of the apparatus operation. In some 
devices, the purchase price is low, but the consumables 
and other operational costs may be much higher. In the 
effect part, not absolute values, but only relations 
between individual devices in each criterion separately 
are taken into consideration. Hence, each criterion can 
be related to other units (e.g. 24 hours vs. one year). 
The respective Saaty´s matrix is given in Table 12, 
and the weights for individual parameters are shown in 
Table 13. All price effects must be assigned the same 
weight. The reason is that a monetary unit spent 
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presents the same burden regardless of what we spend 
it on. Subsequently, these weights are utilized as the 
input to the TOPSIS method to find the most suitable 
device. The criterion matrices R and W are given in 
Table 14 and Table 15. The resulting effects for 
individual devices are given in Table 16. 
 
 
 
Tab. 12: Saaty´s matrix for determining lung ventilator parameter weights. 
 
Parameters 
Cost of 
consumables 
[CZK] 
Cost of spare 
parts [CZK] 
Cost of 
service [CZK] 
Size of 
device 
[mm3] 
Connection to 
clinical information 
system 
Weight of 
ĚĞǀŝĐĞ΀ŬŐ΁ 
Cost of consumables  1 1 1 9 1/5 9 
Cost of spare parts 1 1 1 9 1/5 9 
Cost of service 1 1 1 9 1/5 9 
Size of device 1/9 1/9 1/9 1 1/9 3 
Connection to clinical 
information system 7 7 7 9 1 9 
Weight of device 1/9 1/9 1/9 1/3 1/9 1 
 
Tab. 13: Weights of parameters determined from Saaty´s matrix. 
 
Parameters Weights of parameters 
Cost of consumables 0.157 
Cost of spare parts 0.157 
Cost of service 0.157 
Size of device 0.034 
Connection to clinical information system 0.473 
Weight of device 0.023 
 
Tab. 14: TOPSIS: the normalized criteria matrix R. 
 
Lung ventilator 
Cost of 
consumables 
[CZK] 
Cost of spare 
parts [CZK] 
Cost of service 
[CZK] 
Size of device 
[mm3] 
Connection  
to clinical 
information 
system 
Weight of 
ĚĞǀŝĐĞ΀ŬŐ΁ 
Device #1 0.000 0.000 0.000 0.000 0.000 0.814 
Device #2 0.000 0.000 0.000 0.158 0.577 0.136 
Device #3 0.457 0.881 0.561 0.580 0.577 0.000 
Device #4 0.889 0.473 0.828 0.799 0.577 0.564 
Weight 0.157 0.157 0.157 0.034 0.473 0.023 
 
 
Tab. 15: TOPSIS: the weighted criteria matrix W. 
 
Parametres 
Cost of 
consumables 
[CZK] 
Cost of spare  
parts  
[CZK] 
Cost of service  
[CZK] 
Size of device 
[mm3] 
Connection  
to clinical 
information 
system 
Weight of 
ĚĞǀŝĐĞ΀ŬŐ΁ 
Device #1 0.000 0.000 0.000 0.000 0.000 0.018 
Device #2 0.000 0.000 0.000 0.005 0.273 0.003 
Device #3 0.078 0.138 0.088 0.020 0.273 0.000 
Device #4 0.139 0.074 0.130 0.027 0.273 0.013 
MAX 0.139 0.138 0.130 0.027 0.273 0.018 
MIN 0.000 0.000 0.000 0.000 0.000 0.000 
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Tab. 16: Effects of individual ventilators calculated by 
the TOPSIS method. 
 
Lung ventilator Effect 
Device #1 0.048 
Device #2 0.536 
Device #3 0.799 
Device #4 0.842 
 
 
 
CEA is used, and the decision is made based on the 
effect-cost ratio. The actual prices are substituted for 
the costs, while the results of the MCDA are 
considered the values of the effects. The result is 
shown in Table 17. If we compare outcome for money, 
Device #4 shows the best results; it exhibits a well-
balanced effect and price, while the cheapest, Device 
#1 only ranks third. 
 
Tab. 17: Cost-effectiveness analysis for lung 
ventilators. 
 
Lung 
ventilator Effect 
Cost of 
acquisition 
[CZK] 
CEA=E/C 
[u10-7] ZĂŶŬŝŶŐ 
Device #1 0.048 697 777 0.693 4 
Device #2 0.536 1 100 000 4.870 3 
Device #3 0.799 742 940 10.759 2 
Device #4 0.842 719 755 11.698 1 
 
 
 
Identification of requirements for 
medical device purchase  
 
The methods presented in the previous sections can 
be used for a medical device assessment in any phase 
of its life. Mostly, they are applied at the moment of a 
new device introduction to the health care practice at 
the national regulator level. However, the same 
methods can be employed at the level of an individual 
clinic, hospital, or a group of hospitals when deciding 
about investments, above all about purchasing new 
technology. Then they can be utilized to identify 
necessary parameters of the new device, selection of 
the supplier, or the particular brand. 
Rational decisions in medical device selection are 
based on a proper identification, analysis and 
evaluation of requirements of various involved actors. 
The types of requirements are described in [4]. 
Commercial reasons describe why the project is 
initiated, the objectives to be reached, and the methods 
to be applied to measure the satisfaction.  
Commercial conditions describe the needs of the 
organization as a whole. They are developed and 
defined by means of a company analysis. Requirements 
of involved parties describe needs of individual parties, 
and how the parties will collaborate in the solution. 
Functional requirements describe the system behaviour 
and the required functions it will be able to satisfy. 
Non-functional requirements are those that are not 
directly related with the system behaviour or do not 
affect its functions (e.g. requirements for capacity, 
speed, safety, availability, or information architecture). 
Transitional requirements describe conditions that are 
necessary for the transition of the current state to the 
final one, but will not be needed once the transition has 
been completed. 
The requirements management process consists of 
four basic stages, which are as follows [21]: (i) 
identification; (ii) analysis; (iii) prioritization; (iv) 
validation. The whole process is shown in Figure 2. 
The process can be repeated several times, as new 
knowledge, new interested actors, and new 
requirements can repeat during the application. 
Identification. It is important to understand the 
requirements from the point of view of different types 
of knowledge and functions. A mnemonic tool called 
CATWOE can be used [50]. This is a combination of 
intuition and real-world experience [4]. The goal of the 
CATWOE method is to obtain the so-called rich 
picture, where the problem is described from all angles. 
The ambition is to identify all requirements which 
might be significant in the solution of the problem. 
Analysis. The goal of the analysis is to disclose all 
objectives, system functions, structures and relations to 
the neighbourhood, and to enhance system 
phenomenon algorithmization. 
Prioritization. The next step is requirement 
prioritization. There are several ways to do this that 
differ in time requirements and precision. Each 
particular case requires that a suitable method is 
selected. One possibility is the cost-value approach 
[33] using the analytic hierarchy process [51] (see 
above). Another prioritization method is MoSCoW [7] 
selecting the requirements to four classes (must, 
should, could, won’t). 
Validation. Requirement validation is the last step. It 
checks whether the equipment chosen fulfils all 
requirements. The outcome of the process should be a 
coherent model of requirements responding as much as 
possible to the expectations and possibilities of the 
uses. This creates a compromise between the 
requirements and what can be carried out [26].  
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Fig. 2: The requirements management process. 
 
Expert group composition 
 
The methods described above depend mostly on a 
consensual decision of a panel of experts. Natural 
questions appear whether and how the composition of 
the panel affects the final decision. Although these 
questions have been studied for quite a long time (see 
e.g. [65]), the appropriate panel composition remains a 
controversial issue requiring critical reflection [17]. 
The principal problems are (i) the size of the panel, (ii) 
the expertise of the panellists, (iii) the consistency of 
the panel and (iv) whether the selection of panellists 
should be internal or external [29].  
The size of the panel is important for a reliable and 
quality assessment of all criteria and alternatives [29]. 
A small panel can rapidly come to a consensus, but 
may not take all details into consideration. In the case 
of an excessively large panel, there is a risk that the 
assessment time will be extended, or the panel may not 
come to a consensus within the given number of 
rounds. Of course, large panels also increase the cost of 
the process. Kendall’s W assessing agreement among 
raters [34] can be used to determine the optimum 
expert panel size [29]. The W value ranges from zero 
(no agreement) to one (full agreement). We determine 
H in such a way that 3:!+ Į, where Į is the chosen 
significance level of the statistics W. Practical 
recommendations for calculation of W can be found in 
[58]. 
The expertise of the panellists has been discussed 
since the 1980s without clear results. It is obvious that 
the panellists’ expertise affects the final decision, but 
the advice derived is rather weak [5, 18, 42, 65]. Due to 
a lack of quantitative methods, this paper’s authors 
based their selection on Russian sources [41, 42] 
stressing the formal side of expertise. While the 
methods used [36] seem to be appropriate, the details 
of the evaluation are affected by a different economic 
and cultural realty, and should be remodelled for 
utilization in Europe. Moreover, social psychology has 
demonstrated that expertise itself may not be sufficient 
to obtain accurate judgment, but should be combined 
with diversity [37, 69]. Diversity in a panel proves to 
be beneficial for obtaining useful results in several 
ways: the advice comes from multiple independent 
sources, and the panellists have different backgrounds, 
skills and points of view. The definition of diversity, or 
inconsistency, usually involves demographic 
characteristics as well as aspects related to the 
individuals’ professional experience [18, 38, 69]. 
Group size plays a critical role in determining the 
optimal group: in small groups, the most accurate type 
should be in the majority, whereas in large groups, 
heterogeneity may dominate [29, 37].  
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The least discussed question is whether the experts 
should be chosen from inside the company, or whether 
they should rather be external. Recently, this was 
studied experimentally by Förster and von der Gracht 
[18]. According to their results, internal Delphi surveys 
are applicable when the time frame is limited or 
resources are restricted. Internal topics can be 
discussed, and information is kept confidential; 
moreover, less time is needed to recruit participants 
and their response time is shorter. External Delphi 
panels should be consulted when numerous 
perspectives on different subjects are desired. 
Conducting Delphi surveys with both internal and 
external panels offers the most diverse and plentiful 
opportunities for decision makers. Differing 
expectations can be analyzed to find group patterns and 
match strategies more aptly. 
 
 
Demanding nature of medical 
equipment maintenance  
 
When assessing the economic effectiveness of 
medical devices, next to the purchase price, cost of 
service and consumables have an important role. 
Medical device maintenance planning is crucial, while 
legislation, producer’s instructions and the healthcare 
facility’s own experience should all be considered. 
Healthcare facilities should pay particular attention not 
only to the device’s safety, but also to maintenance 
cost effectiveness. Many hospitals have begun to use 
more cost-effective methods of maintenance planning, 
different from producers´ instructions.  
Medical equipment maintenance demandingness 
assessment is a multiple-criteria decision-making 
problem [61]. The quality of results highly depends on 
the availability of input data; thus, implementation of 
these methods in practice depends on the device 
operation data collection system. The input data are: 
- healthcare facility registration information on 
medical devices; 
- statistics concerning breakdowns and servicing, 
including their cost; and  
- statistics of operation for each device. 
The proper procedure is again based on AHP [49, 
51]. The implementation of the medical devices 
maintenance demand assessment consists of the 
following steps: 
1. Identification of all sufficient and independent 
criteria. The first step in AHP application is designing 
the hierarchic structure of the criteria. All assessment 
criteria should be identifiable and placed at the proper 
level in the hierarchy. Basic criteria are located on the 
second level; each criterion can be divided into several 
sub-criteria of a lower level.  
There are a few approaches to criterion selection. 
Fennigkoh and Smith proposed three basic criteria: 
function, physical risk and maintenance requirements 
[17]. Wang and Levenson introduced two new criteria, 
namely incident history and utilization rate, and 
reinterpreted the function criterion [67]. A new study 
recommends the following six basic criteria: function, 
critical mission, age, risk, recalls and alerts and 
maintenance requirements [61]. 
2. Criterion weight setting. The method of paired 
comparisons is used for setting the weights of 
individual criteria and sub-criteria on all levels, and for 
individual criterion scale quantification (item 4) [51]. 
3. Criterion scale identification. Within an 
individual criterion, the scale contains a priori states 
(categories or classes); for example ‘new’, ‘quite old’ 
and ‘old’ can be three states of device age. In addition, 
rules for how to attach a particular state to the device 
should be given. 
4. Criterion scale quantification. Using paired 
comparisons (see item 2), a number value expressing 
importance within the particular criterion is matched 
with any state.  
5. Individual device assessment in each criterion. 
Each medical device should be assessed in relation to 
all criteria.  
6. The total assessment of the i-th device, Hi, is the 
sum of products of any criterion weight and the 
criterion scale value assigned to the device, i.e.  
 
(14) 
 
where Nt is the number medical devices, hij is the value 
coefficient of evaluation of the i-th device according to 
the j-th criterion, wj is the weight of the j-th criterion on 
the basic level and Nk the number of criteria on the 
basic level. 
The total assessment can be standardized so that the 
resulting value H´i is between 0 and 1, 
 
(15) 
 
The value H´i is a metric enabling decisions 
concerning which category the device belongs to (in 
comparison with the pre-defined limits); the authors’ 
suggestion for the categories that a healthcare facility 
can adopt is given in Table 18.  
 
Tab. 18: Suggested categories and limits [61] 
 
Demanding-
ness category Total value Maintenance strategy 
High 40 % < H i´  100% 
Proactive, predictive or 
maintenance according 
to a schedule 
Medium 20 % < H i´ 40% 
Proactive or 
maintenance according 
to a schedule 
Low 0 %  H i´ 20% Corrective maintenance 
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Conclusions 
 
In 2012, the International Federation for Medical and 
Biological Engineering (IFMBE) identified HTA to be 
of prior importance for ‘Medical and Biological 
Engineering’ and decided to reactivate a special 
division focussed on HTA issues [28]. The objectives 
of this special division are: 
a) to stimulate research and application of new 
developments in HTA; 
b) to reveal the importance of the role of Biomedical 
Engineers in many aspects of HTA and stimulate 
co-operation and professional development and 
growth;  
c) to improve co-operation between Biomedical 
Engineers working in the field of HTA in different 
countries and promote collaboration with other 
specialists including those belonging to other 
scientific societies and, in particular, to medical 
societies; 
d) to facilitate sharing of information, technical and 
professional guidelines for the practices within the 
Healthcare Technology Assessment field and 
promote capacity building;  
e) to promote improvement in the decision-making 
process concerning healthcare technology planning 
and acquisition in healthcare delivery systems. 
This initiative is very topical, as there has been little 
progress in the development of HTA methods for 
medical devices since the situation five years ago, 
when Value in Health initiated a discussion on the 
similarities and/or differences of drugs and medical 
devices from the point of view of HTA studies [14, 
62]. Drummond’s paper [14] listing the main problems 
that a researcher encounters when assessing medical 
devices has been frequently cited. Above all, the 
effectiveness assessment of diagnostic devices requires 
a novel approach. There are incomparably few HTA 
studies focussed on devices compared to those 
focussed on drugs or surgery, and most of them deal 
with therapeutic devices. The recent champions are 
stents and da Vinci systems [44]. 
Utilization of multiple-criteria decision methods 
within health economy has been investigated 
independently [60]. At present, the question is not 
whether, but how to employ them [2]. Medical devices 
seem to be a top candidate for MCDM utilization, as 
they require quite complex assessment. While clinical 
aspects (usually in the form of patient-reported quality 
of life) and cost calculations are assessed in HTA 
studies focussed on drugs and clinical interventions, 
technical and operational aspects should also be 
assessed in devices [13, 29].  
In this paper, we recommend utilization of MCDM 
for medical device assessment in several different 
ways. We do not expect a full replacement of CEA (or 
other cost analyses) by MCDM, but utilizing MCDM; 
rather, MCDM should be utilized within CEA for 
effect (outcome) evaluation. Thus, cost considerations 
are the same as in traditional pharmacoeconomic 
studies, but the clinical effect is replaced by a 
combined measure of important technical parameters 
(possibly in combination with clinical outcomes). This 
enables parameters that are important from the 
engineering point of view to be taken into 
consideration. Hence, problems posed by the IFMBE 
HTA Division can be addressed. Usually, the main 
goal of HTA studies is to make a decision about 
procurement and/or incorporation of the device, often 
on a healthcare facility (hospital) level. 
The methods introduced in this paper were applied to 
various devices including MRIs [29, 30], X-ray devices 
[31], vital signs monitors [32], lung ventilators [45], 
mammography devices [36], electronically and 
mechanically controlled knee systems [36], or remote 
navigation systems of angiography catheters [47]. 
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